小儿风热清口服液治疗儿童急性咽炎/扁桃体炎的多中心随机双盲双模拟阳性药平行对照试验
该多中心、区组随机、双盲双模拟、阳性药平行对照试验纳入120例儿童急性咽炎/扁桃体炎患者,1:1分组接受小儿风热清口服液(XFQOL)加小儿咽扁颗粒(XYG)模拟剂或XYG加XFQOL模拟剂治疗5天。结果显示两组第5天咽痛缓解率均为100%,消失率试验组98.33%、对照组90%,非劣效检验成立;XFQOL在咽痛消失时间和3天缓解率方面可能具有优势,且安全性良好,未发现与治疗相关的不良事件。
要点
- XFQOL治疗儿童急性咽炎/扁桃体炎第5天咽痛消失率非劣效于XYG。
- XFQOL可能缩短咽痛消失时间并提高3天缓解率。
- XFQOL安全性良好,未发现治疗相关不良事件。
核心结论
- XFQOL在儿童急性咽炎/扁桃体炎5天咽痛消失率方面非劣效于XYG。
- 次要终点分析提示XFQOL在症状缓解速度方面可能具有优势,包括更短的咽痛消失时间和更高的3天缓解率。
- XFQOL安全性良好,未发现与治疗相关的不良事件。
研究设计与样本
- 多中心、区组随机、双盲、双模拟、阳性药平行对照临床试验。
- 从三家三级医院纳入120名儿童,按1:1比例随机分配至XFQOL加XYG模拟剂组(n=60)或XYG加XFQOL模拟剂组(n=60),治疗5天。
- 主要疗效终点为第5天咽痛缓解率和消失率,采用Wong-Baker面部表情疼痛评分量表(WBS)评估。
主要发现
- 治疗5天后WBS咽痛评分缓解率两组均为100%。
- 咽痛消失率试验组为98.33%,对照组为90%,风险比及其95%置信区间(试验组/对照组)为0.0833(97.5% CI: 0.0008-0.1659)。
- 非劣效检验表明试验组不劣于对照组。
- 中医证候咽痛起效时间和中医证候咽痛消失时间组间差异有统计学意义,其他指标组间差异均无统计学意义。
- 未发现与XFQOL相关的不良事件。
关键数值与推荐
- 主要疗效终点:第5天咽痛缓解率和消失率,使用WBS评估。
- 次要终点包括WBS缓解和消失时间、第3天WBS缓解率、中医证候积分及单个症状体征变化。
- 安全性通过不良事件和不良反应评估。
临床怎么用
- 对于儿童急性咽炎/扁桃体炎,可考虑使用XFQOL作为治疗选择,其5天咽痛消失率非劣效于XYG。
- XFQOL可能有助于加快咽痛缓解,但需结合患儿具体情况个体化决策。
- 使用XFQOL时需关注安全性,本试验未发现治疗相关不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute pharyngitis and tonsillitis are common in children. Xiao'er Fengreqing Oral Liquid (XFQOL) shows potential benefits in previous studies of pediatric acute upper respiratory tract infections and influenza, but high-quality clinical evidence for pediatric acute pharyngitis/tonsillitis remains limited. METHODS: This multicenter, block-randomized, double-blind, double-dummy, active-controlled trial enrolled 120 children from three tertiary hospitals. Participants were randomly assigned in a 1:1 ratio to receive either XFQOL plus Xiao'er Yanbian Granules (XYG) placebo (XFQOL group, n = 60) or XYG plus XFQOL placebo (control group, n = 60) for 5 days. Primary efficacy endpoints were the day-5 response and disappearance rates of sore throat, assessed using the Wong-Baker Faces Pain Rating Scale (WBS). Secondary endpoints included the time to WBS response and disappearance, the day-3 WBS response rate, and changes in traditional Chinese medicine (TCM) syndrome scores and individual symptoms and signs. Safety was assessed via adverse events and adverse drug reactions. RESULTS: A total of 120 participants were included in the Full Analysis Set. Baseline characteristics were comparable between the groups. Response rate for the WBS sore throat score after 5 days of treatment was 100% in both groups. The disappearance rate was 98.33% in the experimental group and 90% in the control group, with a hazard ratio and its 95% confidence interval (experimental group/control group) of 0.0833 (97.5% CI: 0.0008-0.1659). Non-inferiority testing demonstrated that the experimental group was not inferior to the control group. In addition, statistically significant intergroup differences were observed in TCM syndrome sore throat onset time and TCM syndrome sore throat disappearance time, no statistically significant differences were detected in any other indicators. No related adverse events were attributed to XFQOL. CONCLUSION: XFQOL is non-inferior to XYG for the 5-day sore throat disappearance rate in pediatric acute pharyngitis/tonsillitis. Secondary endpoint analyses suggest potential advantages in the speed of symptom relief, including a shorter time to sore throat disappearance and a higher 3-day response rate, while the effects on TCM syndrome total scores and most individual symptom/sign scores are comparable between groups. Furthermore, XFQOL demonstrates a favorable safety profile, with no treatment-related adverse events identified, suggesting its potential for clinical application. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov, ITMCTR2024000569.
引用
- Shi L, Liu K, Song Y, et al. A multicenter, randomized, double-blind, double-simulated, positive drug parallel-controlled clinical trial to evaluate the efficacy and safety of Xiao'er Fengreqing oral liquid in the treatment of acute pharyngitis/tonsillitis in children. Front Pharmacol. 2026. PMID: 42698666. doi:10.3389/fphar.2026.1878882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。